key: cord-1054883-7y7zqnv6 authors: Fidler, S.; Lewin, S.; Deeks, S.; Sogaard, O.S.; Vanderkerckhove, L.; Collins, S.; Kelly, D.; Singh, J.; Caskey, M.; Frater, J. title: HIV cure research in the time of COVID-19 - antiretroviral therapy treatment interruption trials: a discussion paper. date: 2020-12-06 journal: J Virus Erad DOI: 10.1016/j.jve.2020.100025 sha: a70f2a13c7e360b9fba5cd8a35d8cfb7702cd57e doc_id: 1054883 cord_uid: 7y7zqnv6 This discussion paper addresses the safety of HIV cure studies, particularly those involving stopping antiretroviral therapy, known as an analytic treatment interruption (ATI) in the context of the SARS-CoV-2 pandemic. More than 30 studies listed on ClinicalTrials.gov include an ATI and many others were planned to begin over the next 12 months but most were halted due to the COVID-19 pandemic. We consider the ethics, risks and practical considerations to be taken into account before re-opening HIV cure clinical trials, noting the specific risks of ATI in the context of circulating SARS-CoV-2. Conducting an ATI during the COVID-19 pandemic raises many additional issues that will 55 need to be addressed by clinicians, the community, funders and regulators. Since December 2019 the global SARS-CoV-2 pandemic has dramatically altered daily 58 lives 14 , medical care and research 15 . Limitation of travel and physical distancing were 59 universally adopted, leading to a new clinical environment designed to minimize people's 60 exposure to the health care system. The manner in which care has been provided for people 61 living with HIV has also had to change. To help define policies, many countries drew up guidelines to inform management and care for people living with HIV, whilst SARS-CoV-2 63 continued to circulate at significant levels 16 . At the same time, all non-COVID-19-related clinical research was paused, diverting resources to the COVID-19 response. As the pandemic continues, we need to carefully re-evaluate the risks and benefits of resuming HIV 66 clinical trials, even those including an ATI. As the impact of SARS-CoV-2 declines, it will be possible to restart answering important 70 research questions for the 39 million people globally living with HIV. Generally, most people ensure that any risk to participants i can also be justified by the potential benefit to the larger 74 community 17 . The ethical debate about the pros and cons of an indefinite deferral versus careful 77 resumption of ATI HIV cure studies is important. One option is to indefinitely stop all HIV 78 trials including an ATI until there is a widely available SARS-CoV-2 prophylactic vaccine 18 or 79 effective treatment for COVID-19 disease 19 . Whilst there is a global commitment to both of 80 these goals, the potential for delay with this option is high and many ground-breaking novel HIV remission therapies and approaches currently in trial would remain paused. In the If HIV cure and ATI trials are to continue, each individual study will need to be reviewed and 87 evaluated on a case-by-case basis, once background COVID-19 incidence drops to low 88 levels, as yet undefined. Common mitigation approaches to reduce risk within the field of 89 HIV cure and remission trials might provide a framework to safely reinstitute ATI studies. This will require changes to patient information and informed consent so that study The overall risk of SARS-CoV-2 acquisition is largely related to exposure. This will vary 105 based on: (i) local incidence, (ii) physical circumstances (proximity to people with SARS- There is no evidence to date showing that people living with HIV on ART are at significantly there are theoretical concerns that uncontrolled HIV might increase the risk of SARS-CoV-2 112 infection, predominantly weighted around the concern of decreased immunity due to a low 113 CD4 T cell count rather than evidence for increased risk specifically caused by HIV viraemia. The current recommendation is, therefore, that all people living with HIV should be on ART 22 During periods of increased SARS-CoV-2 incidence in the immediate communities, Any individual testing SARS-CoV-2 positive can defer enrolment until the infection has 221 cleared and rejoin study enrolment at a later date. Re-start of ART will be recommended in the presence of symptoms and a SARS-Cov-2 224 PCR positive test result. Symptoms alone would not trigger ART re-start, unless severe.This 225 will be an important decision to be made on an individual participant basis in discussion with 226 the trial physician. Depending on the individual and the trial protocol, ATI might recommence 227 once symptoms resolve and the PCR result has become negative. As exposure is the main factor driving risk of infection, the background incidence of SARS- The choice to access a vaccine might therefore be added to research protocols and/or 253 having received a vaccine prior to study enrolment and ideally prior to ATI might be added to Often an HIV VL is the study primary endpoint. It is important to ensure capture of sufficient and high quality data to power study and avoid non-validated VL measurements. Increases in local/regional incidence of COVID-19: potential lockdown for second and subsequent waves of COVID-19. All the above strategies might need to be intensified and distancing recommendations change during the study. Division. 30 April 2020. https://www.unicef.org/supply/stories/covid-19-impact-assessment-325 supplies-and-logistics-sourced-unicef-supply-division (accessed 29 July 2020). Declining morbidity and mortality among Apr Recommendations for analytical antiretroviral treatment 307 interruptions in HIV research trials-report of a consensus meeting The impact of COVID-19 on HIV 312 treatment and research: a call to action BHIVA: COVID-19 & shielding: advice for HIV clinicians, GPs and people living with HIV Features of 20 133 UK patients in hospital with 335 COVID-19 using the ISARIC WHO clinical characterization protocol: prospective 336 observational cohort study Disproportionate burden of coronavirus disease 2019 among racial minorities and those in 340 congregate settings among a large cohort of people with HIV COVID-19 and HIV co-infection an 343 emerging consensus Covid-19 and people with HIV infection: Outcomes for 345 Outcomes among HIV-positive patients 348 hospitalized with COVID-19 Clinical 351 outcomes and immunologic characteristics of COVID-19 in people with HIV Coronavirus diseases (COVID-19) outcomes in HIV/AIDS patients: a systematic review HIV and risk of COVID-19 death: a population cohort study from the Western 356 Cape Province, South Africa CoV-2: a storm is raging Systemic effects of inflammation on health during chronic 360 HIV infection Mechanisms of cardiovascular disease in the setting of HIV infection Collateral damage: The impact of the COVID-19 364 pandemic on non-COVID-19 health research The role of antibody testing for SARS-CoV-2: is there 367 one? COVID-19 diagnosis and management; a 369 comprehensive review J Inter A pilot evaluation of whole blood finger-prick sampling 371 for point of care HIV viral load measurement: the UNICORN study Operationalizing HIV cure-related trials with analytic treatment 375 interruptions during the SARS-CoV-2 pandemic; A collaborative approach